At week 48, in children aged 2 to 11 years old, no statistically significant difference was observed in the proportions of patients that achieved the primary endpoint of serum HBV DNA < 1,000 copies/ ml and normal ALT levels between the placebo arm and the adefovir dipivoxil arm.